Mounjaro Long-Term: What Happens When You Stop?

The most direct evidence for what happens when you stop Mounjaro comes from the SURMOUNT-4 trial, specifically designed to answer this question. In this trial, all participants took tirzepatide for 36 weeks during an open-label lead-in period, achieving an average weight loss of approximately 20.9%. Participants were then randomised to either continue tirzepatide or switch to placebo for an additional 52 weeks. The results were stark. Participants who continued tirzepatide lost an additional 5.5% of body weight over the following year. Those who switched to placebo regained approximately 14% of their body weight during the same period, recovering roughly two-thirds of the weight they had lost. However, even after regain, the placebo group was still approximately 9.9% below their original starting weight, meaning they retained about one-third of their total weight loss even a year after stopping. This pattern is consistent with what has been observed with other GLP-1 medications and reflects a fundamental biological reality: obesity is a chronic condition, and the physiological drivers of weight gain (hunger hormones, metabolic adaptation, reduced energy expenditure) reassert themselves when medication is discontinued.

Understanding why weight regain occurs is essential for making informed decisions about long-term treatment. When you lose a significant amount of weight, your body undergoes several compensatory changes that actively promote weight regain. Hormonal changes: Weight loss reduces levels of leptin (the satiety hormone) and increases levels of ghrelin (the hunger hormone). This makes you feel hungrier and less satisfied by meals. These hormonal shifts can persist for years after weight loss and are not fully overcome by willpower alone. Metabolic adaptation: As you lose weight, your resting metabolic rate decreases. Your body becomes more energy-efficient, burning fewer calories at rest than it did at a higher weight. This means you need to eat less just to maintain your lower weight. Neural pathway changes: Weight loss alters brain circuits involved in food reward and appetite regulation. These changes can increase the hedonic appeal of food, making high-calorie foods more tempting. Mounjaro directly counteracts these compensatory mechanisms by mimicking GIP and GLP-1, maintaining appetite suppression, and supporting metabolic function. When the medication is removed, these compensatory mechanisms are no longer counterbalanced, and the biological drive to regain weight reasserts itself. This is not a failure of willpower; it is physiology.

Whether you plan to continue Mounjaro long-term or are considering stopping, these evidence-based strategies can help maximise weight maintenance:

• Continue the medication if possible: The strongest strategy for maintaining weight loss is to continue treatment. If cost is a concern, discuss with your prescriber whether a lower maintenance dose might be effective. Some users maintain their results on a lower dose than was needed for initial weight loss, which reduces the monthly cost. Check our price comparison tool for the most affordable options.
• Prioritise protein intake: Aim for 1.2-1.6g of protein per kilogram of body weight daily. High protein intake helps preserve muscle mass, which supports your metabolic rate.
• Maintain regular physical activity: Exercise is one of the strongest predictors of long-term weight maintenance. Aim for at least 150-300 minutes of moderate activity per week, including resistance training 2-3 times per week.
• Monitor your weight regularly: Weekly weigh-ins allow you to catch small regains early before they become large. If your weight increases by 2-3kg, take action immediately by reviewing your diet and activity levels.
• Establish sustainable eating habits while on Mounjaro: Use the appetite suppression period to develop eating patterns you can maintain long-term. Learn portion control, healthy cooking, and mindful eating while the medication makes these habits easier to establish.
• Consider a gradual taper: If you and your prescriber decide to stop Mounjaro, discuss reducing the dose gradually (for example, stepping down from 10mg to 7.5mg to 5mg over several weeks) rather than stopping abruptly. This may help your body adjust more smoothly, though evidence for this approach is limited.

Tirzepatide has been studied in clinical trials lasting up to 2 years, and post-marketing surveillance has now accumulated several years of real-world data. Here is what the safety evidence shows:

• Gastrointestinal side effects: These are most common during the initial months and after dose increases. For most users, they diminish significantly with continued treatment. Long-term gastrointestinal issues are uncommon.
• Cardiovascular effects: The SURPASS and SURMOUNT trials showed improvements in cardiovascular risk factors including blood pressure, cholesterol, and inflammatory markers. The ongoing SURPASS-CVOT trial is specifically evaluating long-term cardiovascular outcomes. Early data is encouraging.
• Pancreatitis: Cases of pancreatitis have been reported with GLP-1 class medications, including tirzepatide. The risk appears to be low but not zero. Regular monitoring is recommended, and any severe abdominal pain should be investigated promptly.
• Thyroid concerns: In animal studies, GLP-1 receptor agonists caused thyroid C-cell tumours in rodents. This has not been observed in human studies to date, but tirzepatide carries a boxed warning about medullary thyroid carcinoma risk as a precaution. It should not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Gallbladder disease: Rapid weight loss from any cause increases the risk of gallstones. Some tirzepatide users have developed gallbladder problems. This risk is related to the speed of weight loss rather than the medication itself.

Overall, the available evidence supports the safety of tirzepatide for treatment periods of up to 2 years. Longer-term data will continue to accumulate as the medication is used more widely.

One of the biggest practical considerations for long-term Mounjaro use in the UK is cost. As a privately prescribed medication, the ongoing expense can be significant. At current market prices, a year of Mounjaro treatment at a maintenance dose of 10mg costs approximately £2,000 - £3,200 depending on the pharmacy. At 15mg, annual costs can reach £2,400 - £3,800. Over multiple years, this represents a substantial financial commitment. Strategies to manage the long-term cost include:

• Compare prices every time you reorder. Pharmacy pricing changes frequently, and switching to a cheaper provider can save hundreds per year. Our price comparison table makes this quick and easy.
• Discuss a lower maintenance dose. If you have reached your target weight, ask your prescriber whether a lower dose could maintain your results. Dropping from 15mg to 10mg or even 7.5mg reduces cost while potentially still providing adequate appetite suppression.
• Take advantage of subscription pricing. Long-term users benefit most from subscription discounts, which typically save 5-15% compared to one-off orders.
• Factor in the cost of not treating. Obesity-related health conditions (type 2 diabetes, cardiovascular disease, joint problems) have their own costs, both financial and in quality of life. Many users find that the investment in Mounjaro prevents or reduces costs associated with these conditions.
• Watch for NHS developments. NICE is evaluating tirzepatide for weight management. If approved for NHS use, it could become available at no cost or significantly reduced cost for eligible patients. See our NHS availability guide for the latest updates.

Ultimately, the decision about long-term treatment is personal and should be made in partnership with your prescriber, taking into account your health goals, financial situation, and the available evidence. What is clear from the data is that continued treatment produces the best sustained outcomes, and any decision to stop should be made with full awareness of the likely consequences.